Clinical Trial Update: Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating antibody persistence after four MenACWY vaccinations; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• MenACWY (Meningococcal conjugate vaccine A/C/W-135/Y)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 4 | Status: COMPLETED | Results posted: 2019-04-01